ClinicalTrials.gg
TerminatedNCT03443973Updated Jan 17, 2024Results posted

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

A Phase 3 interventional study of Gantenerumab and Placebo in Alzheimer Disease, sponsored by Hoffmann-La Roche. Terminated at 155 sites in 19 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-01-17.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Why this study was terminated
Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
975
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing gantenerumab in Alzheimer Disease — none open to participants now, 1 under way, 1 of them phase 3. gantenerumab · Alzheimer Disease.

Enrollment
3rd of 13
975 · median 194
Started
2018
with 1 other
Phase 3
7 of 13
none open now
Registered
6th of 13
by date
Lead sponsor
9 of 13
Hoffmann-La Roche

Among the 13 studies testing gantenerumab in Alzheimer Disease, this one is the 3rd largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 3, and was the 6th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

None of the 13 studies testing gantenerumab in Alzheimer Disease is open now. The open studies under Alzheimer Disease, anywhere →

About gantenerumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing gantenerumab in Alzheimer Disease as a file.
02

Study summary

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 116. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  • Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment)
  • Evidence of the AD pathological process, as confirmed by CSF tau/A-beta42or amyloid PET scan
  • Demonstrated abnormal memory function
  • score greater than or equal to 22 (≥ 22)
  • Clinical dementia rating-global score (CDR-GS) of 0.5 or 1.0
  • Availability of a reliable study partner who accepts to participate in study procedures throughout the 2 years duration of study
  • If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to screening and until randomization
  • For enrollment in the China extension, patients must have residence in mainland China, Hong Kong, or Taiwan and be of Chinese ancestry
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods

Key Exclusion criteria:

  • Any evidence of a condition other than AD that may affect cognition
  • History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder
  • History or presence of clinically evident systemic vascular disease that in the opinion of the investigator has the potential to affect cognitive function
  • History or presence of clinically evident cerebrovascular disease
  • History or presence of posterior reversible encephalopathy syndrome
  • History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is consistent with a
  • History of severe, CNS trauma
  • History or presence of intracranial mass (e.g., glioma, meningioma) that could potentially impair cognition
  • Presence of infections that affect brain function or history of infections that resulted in neurologic sequelae
  • History or presence of systemic disorders that potentially cause progressive neurologic disease with associated cognitive deficits
  • At risk for suicide in the opinion of the investigator
  • Alcohol and/or substance abuse or dependants in past 2 years
  • Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities
  • Any to brain MRI
  • Unstable or clinically significant cardiovascular, kidney or liver disease
  • Uncontrolled hypertension
  • Unstable or clinically significant cardiovascular disease
  • Abnormal thyroid function
  • Patients with evidence of folic acid deficiency

Exclusion for Open-Label Extension (OLE):

  • Discontinued from study treatment during the double-blind treatment period
  • Received any other medication during the double-blind treatment period or after the end of double-blind treatment
  • Participation in the OLE deemed inappropriate by the investigator
  • Presence of ARIA-E findings at the Week 116 MRI scan
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
975 participants (actual)

Study arms

  • Experimental
    Gantenerumab

    Gantenerumab will be administered as SC injections with gradual uptitration.

    Drug: Gantenerumab

  • Placebo comparator
    Placebo

    Placebo will be administered as SC injections with gradual uptitration.

    Drug: Placebo

Interventions

  • Gantenerumab will be administered as per the schedule specified in the respective arm.

    Also known as: RO4909832

  • DrugPlacebo

    Placebo matching to gantenerumab will be administered as per the schedule specified in the respective arm.

06

What researchers measure

Primary outcomes

  1. DBT Period: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB

    CDR was derived through semi-structured interview with the participant and an appropriate informant, and it rated impairment across six domains: memory, orientation, judgment, and problem solving, community affairs, home and hobbies, and personal care on a 5-point scale for which 0=no impairment, 0.5=questionable impairment, and 1, 2, and 3=mild, moderate, and severe impairment, respectively. The CDR-SB is based on summing each of the domain box scores with total score ranging from 0-18 with higher scores reflecting greater cognitive and functional impairment. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 116

  2. OLE Period: Number of Participants With Adverse Events (AEs)

    An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.

    Time frame: From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 48 weeks)

  3. OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS=assessment tool used to assess lifetime suicidality of a participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, \& attempts with actual/potential lethality. Categories have binary responses (yes/no) \& include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher= suicidal ideation or behavior. Categories with non-zero values are only reported here.

    Time frame: From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 48 weeks)

  4. OLE Period : Number of Participants With Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) Confirmed by MRI

    ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. ARIA-H (H for hemosiderosis) are small foci of signal loss observed on MRI sequences sensitive for paramagnetic tissue properties and comprise cerebral microbleeds (small foci of bleeding in the brain parenchyma) and leptomeningeal hemosiderosis (small foci of bleeding on the surface of the brain). These changes also occur sporadically in AD.

    Time frame: From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 48 weeks)

  5. OLE Period: Number of Participants With Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by Magnetic Resonance Imaging (MRI)

    ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. In ARIA-E, (E for oedema or effusion), oedema can be seen in different areas of the brain on MRI, representing fluid leakage into the brain parenchyma or sulcal spaces.

    Time frame: From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 48 weeks)

  6. OLE Period: Number of Participants With Injection-Site Reactions

    An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. Local injection reactions (or injection site reactions) are defined as AEs related to the injection site that occur during or within 24 hours after study drug administration that are judged to be related to the study drug injection.

    Time frame: From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 48 weeks)

Secondary outcomes

  1. DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 13 (ADAS-Cog13) Score

    The ADAS-Cog13 total score includes all of the items in the ADAS-Cog11 in addition to delayed word recall and the number cancellation. For the ADAS-cog 13 the range is 0-85 (score range for Delayed Word Recall \[DWR\] score is 0-10 and for Number Cancellation \[NC\] is 0-5, thus the score is ADAS-cog 11\[0-70\] plus the scores for DWR and NC). A higher score indicates worse performance. A negative change from baseline indicates improvement in cognitive function.

    Time frame: Baseline, Week 116

  2. DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) Total Score

    ADCS-ADL is a 23-item rater-administered, observer-reported outcome (ObsRO) that captures a participant's ability to perform basic activities of daily living (e.g., eating and toileting) and more complex ADL or instrumental activities of daily living (iADL, e.g., using the telephone, managing finances, preparing a meal). Total score ranges from 0-78, with higher scores reflecting better functioning. A positive change from baseline indicates improvement.

    Time frame: Baseline, Week 116

  3. DBT Period: Change From Baseline to Week 116 in Functional Activities Questionnaire (FAQ) Score

    FAQ is a rater-administered ObsRO (informant-based measure) that measures a participant's functional ability to perform complex higher-order activities. The observer provides performance ratings of the target person on ten complex higher-order activities. Total score that ranges from 0-30, with higher scores reflecting greater functional impairment. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 116

  4. DBT Period: Change From Baseline to Week 116 in Mini-Mental State Examination (MMSE) Total Score

    MMSE is a rater-administered performance-based outcome (PerfO) that includes a set of standardized questions used to evaluate possible cognitive impairment and help stage the severity level of this impairment. The questions target six areas: orientation, registration, attention, short-term recall, language, and constructional praxis/visuospatial abilities. Total score ranges from 0-30, with lower scores indicating greater impairment. A positive change from baseline indicates improvement.

    Time frame: Baseline, Week 116

  5. DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 11 (ADAS-Cog11) Score

    The ADAS-Cog11 was designed to measure cognitive symptom change in participants with Alzheimer's Disease (AD) and consisted of 11 tasks. The standard 11 items (and corresponding score range) were: word recall (0-10), commands (0-5), constructional praxis (0-5), naming objects and fingers (0-5), ideational praxis (0-5), orientation (0-8), word recognition (0-12), spoken language ability (0-5), comprehension of spoken language (0-5), word-finding difficulty (0-5), and remembering test instructions (0-5). The test included 7 performance items and 4 clinician-rated items. The ADAS-Cog11 total score was the sum of all 11 individual items, with a total score ranging from 0 (no impairment) to 70 (severe impairment). Higher scores indicated more severe cognitive impairment. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 116

  6. DBT Period: Change From Baseline to Week 116 in Verbal Fluency Task (VFT) Score

    VFT is a rater administered PerfO that measures speed and flexibility of verbal thought with a total score that ranges from 0-99 (lower scores indicating lower performance). A positive change from baseline indicates improvement.

    Time frame: Baseline, Week 116

  7. DBT Period: Change From Baseline to Week 116 in the Coding (Digit Symbol Substitution Test [DSST]) Subtest

    Coding, also called DSST is a rater administered PerfO that measures speed of processing and associative memory with a total score that ranges from 0-135 (lower scores indicating lower performance). The DSST was adapted from the Wechsler Adult Intelligence Scale. The 120-second version of the test was used in this study. Positive change from baseline indicates improvement.

    Time frame: Baseline, Week 116

  8. DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) Instrumental Score

    The ADCS-iADL measures activities such as using the telephone, shopping and preparing a meal. The ADCS-iADL consists of 16 questions with a score range of 0 to 56 where a higher score represents better function. Positive change from baseline indicates improvement.

    Time frame: Baseline, Week 116

  9. DBT Period: Number of Participants With AEs

    An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.

    Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 128 weeks)

  10. DBT Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS

    C-SSRS=assessment tool used to assess lifetime suicidality of a participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, \& attempts with actual/potential lethality. Categories have binary responses (yes/no) \& include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher= suicidal ideation or behavior. Categories with non-zero values are only reported here.

    Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 128 weeks)

  11. DBT Period: Number of Participants With ARIA-E Confirmed by MRI

    ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. In ARIA-E, (E for oedema or effusion), oedema can be seen in different areas of the brain on MRI, representing fluid leakage into the brain parenchyma or sulcal spaces.

    Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 128 weeks)

  12. DBT Period: Number of Participants With ARIA-H Confirmed by MRI

    ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. ARIA-H (H for hemosiderosis) are small foci of signal loss observed on MRI sequences sensitive for paramagnetic tissue properties and comprise cerebral microbleeds (small foci of bleeding in the brain parenchyma) and leptomeningeal hemosiderosis (small foci of bleeding on the surface of the brain). These changes also occur sporadically in AD.

    Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 128 weeks)

  13. DBT Period: Number of Participants With Injection-Site Reactions

    An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. Local injection reactions (or injection site reactions) are defined as AEs related to the injection site that occur during or within 24 hours after study drug administration that are judged to be related to the study drug injection.

    Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 128 weeks)

  14. DBT Period: Number of Participants With Anti-Drug Antibodies (ADA) to Gantenerumab

    The number of participants with positive results for ADA against gantenerumab at any of the post-baseline assessment time-points were reported. Participant with an ADA assay result from at least one post-baseline sample was defined as a post-baseline evaluable participant. Treatment Emergent ADA = A participant with a negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result.

    Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 128 weeks)

  15. Change From Baseline to Week 116 in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) Scan in a Subset of Participants

    Brain amyloid load over time was assessed using \[18F\] florbetaben or \[18F\] flutemetamol tracers. These are PET radioligand selective to amyloid. Amyloid PET burden was measured in a composite region of interest (ROI) by using standardized uptake value ratio (SUVR) mapped to the centiloid scale. The weighted composite target region are composed of (both left and right side): frontal lobe, parietal lobe, temporal lobe lateral, cingulum posterior and anterior cingulate gyrus. The reference region used to normalize the composite region was the whole cerebellum. The centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan.

    Time frame: Baseline, Week 116

  16. Change From Baseline to Week 116 in Brain Tau Load, as Measured by Tau PET Scan in a Subset of Participants

    Change in tau load= how much neurofibrillary tau pathology is present in brain assessed by PET Scan. Tau PET radioligand used was \[18F\] GTP1. Tau load was measured using SUVR in 4 composite target ROIs: Temporal target region included (both left \& right)=anterior \&posterior superior temporal gyrus, posterior temporal lobe, fusiform gyrus, \&middle \&inferior temporal gyrus; Medial temporal region excluding hippocampus included (both left \& right): amygdala, parahippocampus \& anterior medial \& lateral temporal lobe; Frontal lobe (both left \& right) \& Parietal lobe (both left \& right). Inferior cerebellar grey matter=reference region for calculating SUVRs for 4 target regions. Tau-PET-mITT analysis set=all participants in ITT analysis set who participated in Tau PET sub-study \& had at least one Tau PET scan with valid quantitative measurement \& who did not withdraw from Tau PET substudy before randomization. Overall number analyzed=number of participants with data available for analysis.

    Time frame: Baseline, Week 116

  17. DBT Period: Percent Change From Baseline to Week 116 in Cerebrospinal Fluid (CSF) Marker of Disease in a Subset of Participants - Neurofilament Light Chain (NFL)

    NFL is a neuronal cytoplasmic protein highly expressed in large, myelinated axons. Its levels increase in CSF and blood proportionally to the degree of axonal damage in a variety of neurological disorders, including AD.

    Time frame: Baseline, Week 116

  18. DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Neurogranin

    Time frame: Baseline, Week 116

  19. DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Total Tau (tTau)

    CSF biomarker tTau has been considered as a general marker of neurodegeneration. An elevation in levels of tau, as well as specific pTau species, is thought to be a marker for progressive cellular degeneration in AD.

    Time frame: Baseline, Week 116

  20. DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Phosphorylated Tau (pTau-181)

    CSF phospho-tau is an indicator of neuronal injury and neurodegeneration. CSF biomarker tTau has been considered as a general marker of neurodegeneration. An elevation in levels of pTau species, is thought to be a marker for progressive cellular degeneration in AD.

    Time frame: Baseline, Week 116

Other outcomes

  1. Plasma Concentration of Gantenerumab

    Time frame: Pre-dose on Days 1, Weeks 24, 52 and 76; Post-dose on Day 4, Weeks 41, 103, and 115

07

Results

Posted Jan 17, 2024

Participant flow

Participants were enrolled in the study across 151 investigative sites in 18 countries from 22 August 2018 to 28 November 2022.

Double-blind Treatment Period
Participant flow — Double-blind Treatment Period
MilestonePlacebo: DBTGantenerumab: DBTPlacebo (DBT) to Gantenerumab: Open-label Extension (OLE)Gantenerumab (DBT) to Gantenerumab: OLE
Started47749800
Safety-evaluable set47450100
Completed39737200
Not completed8012600
Withdrew: Adverse event51900
Withdrew: Death5700
Withdrew: Lack of efficacy1100
Withdrew: Lost to follow-up0100
Withdrew: Reason not specified91100
Withdrew: Physician decision5600
Withdrew: Protocol deviation1200
Withdrew: Withdrawal by subject547900
Open-label Extension Period
Participant flow — Open-label Extension Period
MilestonePlacebo: DBTGantenerumab: DBTPlacebo (DBT) to Gantenerumab: Open-label Extension (OLE)Gantenerumab (DBT) to Gantenerumab: OLE
Started001314
Completed00813
Not completed0051
Withdrew: Reason not specified0030
Withdrew: Withdrawal by subject0021

Outcome measures

PrimaryDBT Period: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB

CDR was derived through semi-structured interview with the participant and an appropriate informant, and it rated impairment across six domains: memory, orientation, judgment, and problem solving, community affairs, home and hobbies, and personal care on a 5-point scale for which 0=no impairment, 0.5=questionable impairment, and 1, 2, and 3=mild, moderate, and severe impairment, respectively. The CDR-SB is based on summing each of the domain box scores with total score ranging from 0-18 with higher scores reflecting greater cognitive and functional impairment. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 116
Reported as:
Mean · score on a scale
DBT Period: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB
score on a scalePlacebo: DBTGantenerumab: DBT
DBT Period: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB3.01 ± 0.152.82 ± 0.14
Statistical analysis
  • Placebo: DBT vs Gantenerumab: DBT · ANCOVA · p = 0.2998 · Difference in adjusted mean: -0.19 · 95% CI -0.55 to 0.17
PrimaryOLE Period: Number of Participants With Adverse Events (AEs)

An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.

Time frame:
From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 48 weeks)
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Adverse Events (AEs)
ParticipantsPlacebo (DBT) to Gantenerumab: Open-label Extension (OLE)Gantenerumab (DBT) to Gantenerumab: OLE
OLE Period: Number of Participants With Adverse Events (AEs)86
PrimaryOLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)

C-SSRS=assessment tool used to assess lifetime suicidality of a participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, \& attempts with actual/potential lethality. Categories have binary responses (yes/no) \& include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher= suicidal ideation or behavior. Categories with non-zero values are only reported here.

Time frame:
From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 48 weeks)
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsPlacebo (DBT) to Gantenerumab: Open-label Extension (OLE)Gantenerumab (DBT) to Gantenerumab: OLE
Suicidal Ideation: Passive10
Suicidal Ideation: Active-Method, but no Intent or Plan10
Suicidal Ideation: No Event1013
Suicidal Behavior: No event1213
Self-injurious Behavior Without Suicidal Intent: No event1213
PrimaryOLE Period : Number of Participants With Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) Confirmed by MRI

ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. ARIA-H (H for hemosiderosis) are small foci of signal loss observed on MRI sequences sensitive for paramagnetic tissue properties and comprise cerebral microbleeds (small foci of bleeding in the brain parenchyma) and leptomeningeal hemosiderosis (small foci of bleeding on the surface of the brain). These changes also occur sporadically in AD.

Time frame:
From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 48 weeks)
Reported as:
Count of participants · Participants
OLE Period : Number of Participants With Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) Confirmed by MRI
ParticipantsPlacebo (DBT) to Gantenerumab: Open-label Extension (OLE)Gantenerumab (DBT) to Gantenerumab: OLE
OLE Period : Number of Participants With Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) Confirmed by MRI21
PrimaryOLE Period: Number of Participants With Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by Magnetic Resonance Imaging (MRI)

ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. In ARIA-E, (E for oedema or effusion), oedema can be seen in different areas of the brain on MRI, representing fluid leakage into the brain parenchyma or sulcal spaces.

Time frame:
From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 48 weeks)
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by Magnetic Resonance Imaging (MRI)
ParticipantsPlacebo (DBT) to Gantenerumab: Open-label Extension (OLE)Gantenerumab (DBT) to Gantenerumab: OLE
OLE Period: Number of Participants With Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by Magnetic Resonance Imaging (MRI)01
PrimaryOLE Period: Number of Participants With Injection-Site Reactions

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. Local injection reactions (or injection site reactions) are defined as AEs related to the injection site that occur during or within 24 hours after study drug administration that are judged to be related to the study drug injection.

Time frame:
From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 48 weeks)
Reported as:
Count of participants · Participants
OLE Period: Number of Participants With Injection-Site Reactions
ParticipantsPlacebo (DBT) to Gantenerumab: Open-label Extension (OLE)Gantenerumab (DBT) to Gantenerumab: OLE
OLE Period: Number of Participants With Injection-Site Reactions01
SecondaryDBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 13 (ADAS-Cog13) Score

The ADAS-Cog13 total score includes all of the items in the ADAS-Cog11 in addition to delayed word recall and the number cancellation. For the ADAS-cog 13 the range is 0-85 (score range for Delayed Word Recall \[DWR\] score is 0-10 and for Number Cancellation \[NC\] is 0-5, thus the score is ADAS-cog 11\[0-70\] plus the scores for DWR and NC). A higher score indicates worse performance. A negative change from baseline indicates improvement in cognitive function.

Time frame:
Baseline, Week 116
Reported as:
Mean · score on a scale
DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 13 (ADAS-Cog13) Score
score on a scalePlacebo: DBTGantenerumab: DBT
DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 13 (ADAS-Cog13) Score7.94 ± 0.496.66 ± 0.42
Statistical analysis
  • Placebo: DBT vs Gantenerumab: DBT · ANCOVA · p = 0.0273 · Difference in adjusted mean: -1.28 · 95% CI -2.41 to -0.14
SecondaryDBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) Total Score

ADCS-ADL is a 23-item rater-administered, observer-reported outcome (ObsRO) that captures a participant's ability to perform basic activities of daily living (e.g., eating and toileting) and more complex ADL or instrumental activities of daily living (iADL, e.g., using the telephone, managing finances, preparing a meal). Total score ranges from 0-78, with higher scores reflecting better functioning. A positive change from baseline indicates improvement.

Time frame:
Baseline, Week 116
Reported as:
Mean · score on a scale
DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) Total Score
score on a scalePlacebo: DBTGantenerumab: DBT
DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) Total Score-9.26 ± 0.62-8.44 ± 0.58
Statistical analysis
  • Placebo: DBT vs Gantenerumab: DBT · ANCOVA · p = 0.2918 · Difference in adjusted mean: 0.82 · 95% CI -0.70 to 2.34
SecondaryDBT Period: Change From Baseline to Week 116 in Functional Activities Questionnaire (FAQ) Score

FAQ is a rater-administered ObsRO (informant-based measure) that measures a participant's functional ability to perform complex higher-order activities. The observer provides performance ratings of the target person on ten complex higher-order activities. Total score that ranges from 0-30, with higher scores reflecting greater functional impairment. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 116
Reported as:
Mean · score on a scale
DBT Period: Change From Baseline to Week 116 in Functional Activities Questionnaire (FAQ) Score
score on a scalePlacebo: DBTGantenerumab: DBT
DBT Period: Change From Baseline to Week 116 in Functional Activities Questionnaire (FAQ) Score6.72 ± 0.335.86 ± 0.31
Statistical analysis
  • Placebo: DBT vs Gantenerumab: DBT · ANCOVA · p = 0.0438 · Difference in adjusted mean: -0.86 · 95% CI -1.70 to -0.02
SecondaryDBT Period: Change From Baseline to Week 116 in Mini-Mental State Examination (MMSE) Total Score

MMSE is a rater-administered performance-based outcome (PerfO) that includes a set of standardized questions used to evaluate possible cognitive impairment and help stage the severity level of this impairment. The questions target six areas: orientation, registration, attention, short-term recall, language, and constructional praxis/visuospatial abilities. Total score ranges from 0-30, with lower scores indicating greater impairment. A positive change from baseline indicates improvement.

Time frame:
Baseline, Week 116
Reported as:
Mean · score on a scale
DBT Period: Change From Baseline to Week 116 in Mini-Mental State Examination (MMSE) Total Score
score on a scalePlacebo: DBTGantenerumab: DBT
DBT Period: Change From Baseline to Week 116 in Mini-Mental State Examination (MMSE) Total Score-4.53 ± 0.22-4.00 ± 0.20
Statistical analysis
  • Placebo: DBT vs Gantenerumab: DBT · ANCOVA · p = 0.0566 · Difference in adjusted mean: 0.52 · 95% CI -0.01 to 1.06
SecondaryDBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 11 (ADAS-Cog11) Score

The ADAS-Cog11 was designed to measure cognitive symptom change in participants with Alzheimer's Disease (AD) and consisted of 11 tasks. The standard 11 items (and corresponding score range) were: word recall (0-10), commands (0-5), constructional praxis (0-5), naming objects and fingers (0-5), ideational praxis (0-5), orientation (0-8), word recognition (0-12), spoken language ability (0-5), comprehension of spoken language (0-5), word-finding difficulty (0-5), and remembering test instructions (0-5). The test included 7 performance items and 4 clinician-rated items. The ADAS-Cog11 total score was the sum of all 11 individual items, with a total score ranging from 0 (no impairment) to 70 (severe impairment). Higher scores indicated more severe cognitive impairment. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 116
Reported as:
Mean · score on a scale
DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 11 (ADAS-Cog11) Score
score on a scalePlacebo: DBTGantenerumab: DBT
DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 11 (ADAS-Cog11) Score6.97 ± 0.465.77 ± 0.38
Statistical analysis
  • Placebo: DBT vs Gantenerumab: DBT · ANCOVA · p = 0.0260 · Difference in adjusted mean: -1.19 · 95% CI -2.24 to -0.14
SecondaryDBT Period: Change From Baseline to Week 116 in Verbal Fluency Task (VFT) Score

VFT is a rater administered PerfO that measures speed and flexibility of verbal thought with a total score that ranges from 0-99 (lower scores indicating lower performance). A positive change from baseline indicates improvement.

Time frame:
Baseline, Week 116
Reported as:
Mean · score on a scale
DBT Period: Change From Baseline to Week 116 in Verbal Fluency Task (VFT) Score
score on a scalePlacebo: DBTGantenerumab: DBT
DBT Period: Change From Baseline to Week 116 in Verbal Fluency Task (VFT) Score-2.68 ± 0.22-2.71 ± 0.21
Statistical analysis
  • Placebo: DBT vs Gantenerumab: DBT · ANCOVA · p = 0.9086 · Difference in adjusted mean: -0.03 · 95% CI -0.59 to 0.52
SecondaryDBT Period: Change From Baseline to Week 116 in the Coding (Digit Symbol Substitution Test [DSST]) Subtest

Coding, also called DSST is a rater administered PerfO that measures speed of processing and associative memory with a total score that ranges from 0-135 (lower scores indicating lower performance). The DSST was adapted from the Wechsler Adult Intelligence Scale. The 120-second version of the test was used in this study. Positive change from baseline indicates improvement.

Time frame:
Baseline, Week 116
Reported as:
Mean · score on a scale
DBT Period: Change From Baseline to Week 116 in the Coding (Digit Symbol Substitution Test [DSST]) Subtest
score on a scalePlacebo: DBTGantenerumab: DBT
DBT Period: Change From Baseline to Week 116 in the Coding (Digit Symbol Substitution Test [DSST]) Subtest-6.90 ± 0.59-5.49 ± 0.55
Statistical analysis
  • Placebo: DBT vs Gantenerumab: DBT · ANCOVA · p = 0.0629 · Difference in adjusted mean: 1.41 · 95% CI -0.08 to 2.90
SecondaryDBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) Instrumental Score

The ADCS-iADL measures activities such as using the telephone, shopping and preparing a meal. The ADCS-iADL consists of 16 questions with a score range of 0 to 56 where a higher score represents better function. Positive change from baseline indicates improvement.

Time frame:
Baseline, Week 116
Reported as:
Mean · score on a scale
DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) Instrumental Score
score on a scalePlacebo: DBTGantenerumab: DBT
DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) Instrumental Score-8.22 ± 0.53-7.43 ± 0.49
Statistical analysis
  • Placebo: DBT vs Gantenerumab: DBT · ANCOVA · p = 0.2348 · Difference in adjusted mean: 0.79 · 95% CI -0.51 to 2.09
SecondaryDBT Period: Number of Participants With AEs

An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.

Time frame:
From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 128 weeks)
Reported as:
Count of participants · Participants
DBT Period: Number of Participants With AEs
ParticipantsPlacebo: DBTGantenerumab: DBT
DBT Period: Number of Participants With AEs409451
SecondaryDBT Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS

C-SSRS=assessment tool used to assess lifetime suicidality of a participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, \& attempts with actual/potential lethality. Categories have binary responses (yes/no) \& include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher= suicidal ideation or behavior. Categories with non-zero values are only reported here.

Time frame:
From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 128 weeks)
Reported as:
Count of participants · Participants
DBT Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS
ParticipantsPlacebo: DBTGantenerumab: DBT
Suicidal Ideation: Passive2012
Suicidal Ideation: Active-Nonspecific42
Suicidal Ideation: Active-Method, But No Intent or Plan22
Suicidal Ideation: Active-Method and Intent, But No Plan11
Suicidal Ideation: Active-Method, Intent, and Plan02
Suicidal Ideation: No Event437464
Suicidal Behavior: No Event464483
Self-injurious Behavior, No Suicidal Intent02
Self-injurious Behavior Without Suicidal Intent: No Event464481
SecondaryDBT Period: Number of Participants With ARIA-E Confirmed by MRI

ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. In ARIA-E, (E for oedema or effusion), oedema can be seen in different areas of the brain on MRI, representing fluid leakage into the brain parenchyma or sulcal spaces.

Time frame:
From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 128 weeks)
Reported as:
Count of participants · Participants
DBT Period: Number of Participants With ARIA-E Confirmed by MRI
ParticipantsPlacebo: DBTGantenerumab: DBT
DBT Period: Number of Participants With ARIA-E Confirmed by MRI18128
SecondaryDBT Period: Number of Participants With ARIA-H Confirmed by MRI

ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. ARIA-H (H for hemosiderosis) are small foci of signal loss observed on MRI sequences sensitive for paramagnetic tissue properties and comprise cerebral microbleeds (small foci of bleeding in the brain parenchyma) and leptomeningeal hemosiderosis (small foci of bleeding on the surface of the brain). These changes also occur sporadically in AD.

Time frame:
From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 128 weeks)
Reported as:
Count of participants · Participants
DBT Period: Number of Participants With ARIA-H Confirmed by MRI
ParticipantsPlacebo: DBTGantenerumab: DBT
DBT Period: Number of Participants With ARIA-H Confirmed by MRI57109
SecondaryDBT Period: Number of Participants With Injection-Site Reactions

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. Local injection reactions (or injection site reactions) are defined as AEs related to the injection site that occur during or within 24 hours after study drug administration that are judged to be related to the study drug injection.

Time frame:
From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 128 weeks)
Reported as:
Count of participants · Participants
DBT Period: Number of Participants With Injection-Site Reactions
ParticipantsPlacebo: DBTGantenerumab: DBT
DBT Period: Number of Participants With Injection-Site Reactions3175
SecondaryDBT Period: Number of Participants With Anti-Drug Antibodies (ADA) to Gantenerumab

The number of participants with positive results for ADA against gantenerumab at any of the post-baseline assessment time-points were reported. Participant with an ADA assay result from at least one post-baseline sample was defined as a post-baseline evaluable participant. Treatment Emergent ADA = A participant with a negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result.

Time frame:
From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 128 weeks)
Reported as:
Count of participants · Participants
DBT Period: Number of Participants With Anti-Drug Antibodies (ADA) to Gantenerumab
ParticipantsGantenerumab: DBT
DBT Period: Number of Participants With Anti-Drug Antibodies (ADA) to Gantenerumab12
SecondaryChange From Baseline to Week 116 in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) Scan in a Subset of Participants

Brain amyloid load over time was assessed using \[18F\] florbetaben or \[18F\] flutemetamol tracers. These are PET radioligand selective to amyloid. Amyloid PET burden was measured in a composite region of interest (ROI) by using standardized uptake value ratio (SUVR) mapped to the centiloid scale. The weighted composite target region are composed of (both left and right side): frontal lobe, parietal lobe, temporal lobe lateral, cingulum posterior and anterior cingulate gyrus. The reference region used to normalize the composite region was the whole cerebellum. The centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan.

Time frame:
Baseline, Week 116
Reported as:
Mean · score on a scale
Change From Baseline to Week 116 in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) Scan in a Subset of Participants
score on a scalePlacebo: DBTGantenerumab: DBT
Change From Baseline to Week 116 in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) Scan in a Subset of Participants8.46 ± 2.768-48.00 ± 2.845
Statistical analysis
  • Placebo: DBT vs Gantenerumab: DBT · Mixed Model for Repeated Measures · p = <.0001 · Difference in adjusted means: -56.46 · 95% CI -64.36 to -48.56
SecondaryChange From Baseline to Week 116 in Brain Tau Load, as Measured by Tau PET Scan in a Subset of Participants

Change in tau load= how much neurofibrillary tau pathology is present in brain assessed by PET Scan. Tau PET radioligand used was \[18F\] GTP1. Tau load was measured using SUVR in 4 composite target ROIs: Temporal target region included (both left \& right)=anterior \&posterior superior temporal gyrus, posterior temporal lobe, fusiform gyrus, \&middle \&inferior temporal gyrus; Medial temporal region excluding hippocampus included (both left \& right): amygdala, parahippocampus \& anterior medial \& lateral temporal lobe; Frontal lobe (both left \& right) \& Parietal lobe (both left \& right). Inferior cerebellar grey matter=reference region for calculating SUVRs for 4 target regions. Tau-PET-mITT analysis set=all participants in ITT analysis set who participated in Tau PET sub-study \& had at least one Tau PET scan with valid quantitative measurement \& who did not withdraw from Tau PET substudy before randomization. Overall number analyzed=number of participants with data available for analysis.

Time frame:
Baseline, Week 116
Reported as:
Mean · SUVR
Change From Baseline to Week 116 in Brain Tau Load, as Measured by Tau PET Scan in a Subset of Participants
SUVRPlacebo: DBTGantenerumab: DBT
ROI: Temporal Composite Region0.12 ± 0.0180.13 ± 0.014
ROI: Medial Temporal Composite Region [not including the Hippocampus]0.08 ± 0.0140.09 ± 0.011
ROI: Frontal Lobe0.08 ± 0.0120.08 ± 0.009
ROI: Parietal Lobe0.09 ± 0.0200.09 ± 0.016
Statistical analysis
  • Placebo: DBT vs Gantenerumab: DBT · Mixed Model for Repeated Measures · p = 0.7816 · Difference in adjusted mean: 0.01 · 95% CI -0.04 to 0.05
  • Placebo: DBT vs Gantenerumab: DBT · Mixed Model for Repeated Measures · p = 0.6203 · Difference in adjusted means: 0.01 · 95% CI -0.03 to 0.05
  • Placebo: DBT vs Gantenerumab: DBT · Mixed Model for Repeated Measures · p = 0.7754 · Difference in adjusted means: 0.00 · 95% CI -0.03 to 0.03
  • Placebo: DBT vs Gantenerumab: DBT · Mixed Model for Repeated Measures · p = 0.9022 · Difference in adjusted means: 0.00 · 95% CI -0.05 to 0.05
SecondaryDBT Period: Percent Change From Baseline to Week 116 in Cerebrospinal Fluid (CSF) Marker of Disease in a Subset of Participants - Neurofilament Light Chain (NFL)

NFL is a neuronal cytoplasmic protein highly expressed in large, myelinated axons. Its levels increase in CSF and blood proportionally to the degree of axonal damage in a variety of neurological disorders, including AD.

Time frame:
Baseline, Week 116
Reported as:
Geometric mean · percent change in NFL
DBT Period: Percent Change From Baseline to Week 116 in Cerebrospinal Fluid (CSF) Marker of Disease in a Subset of Participants - Neurofilament Light Chain (NFL)
percent change in NFLPlacebo: DBTGantenerumab: DBT
DBT Period: Percent Change From Baseline to Week 116 in Cerebrospinal Fluid (CSF) Marker of Disease in a Subset of Participants - Neurofilament Light Chain (NFL)25.5 (15.83 to 35.97)8.9 (0.60 to 17.83)
Statistical analysis
  • Placebo: DBT vs Gantenerumab: DBT · ANCOVA · p = 0.014 · Percent difference in geometric mean: -13.2 · 95% CI -22.51 to -2.87
SecondaryDBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Neurogranin
Time frame:
Baseline, Week 116
Reported as:
Geometric mean · percent change in neurogranin
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Neurogranin
percent change in neurograninPlacebo: DBTGantenerumab: DBT
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Neurogranin-6.1 (-11.99 to 0.12)-19.6 (-24.66 to -14.30)
Statistical analysis
  • Placebo: DBT vs Gantenerumab: DBT · ANCOVA · p = <0.001 · Percent difference in geometric mean: -14.4 · 95% CI -21.88 to -6.21
SecondaryDBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Total Tau (tTau)

CSF biomarker tTau has been considered as a general marker of neurodegeneration. An elevation in levels of tau, as well as specific pTau species, is thought to be a marker for progressive cellular degeneration in AD.

Time frame:
Baseline, Week 116
Reported as:
Geometric mean · percent change in tTau
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Total Tau (tTau)
percent change in tTauPlacebo: DBTGantenerumab: DBT
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Total Tau (tTau)1.8 (-4.46 to 8.45)-16.4 (-21.55 to -10.87)
Statistical analysis
  • Placebo: DBT vs Gantenerumab: DBT · ANCOVA · p = <0.001 · Percent difference in geometric mean: -17.8 · 95% CI -24.92 to -10.11
SecondaryDBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Phosphorylated Tau (pTau-181)

CSF phospho-tau is an indicator of neuronal injury and neurodegeneration. CSF biomarker tTau has been considered as a general marker of neurodegeneration. An elevation in levels of pTau species, is thought to be a marker for progressive cellular degeneration in AD.

Time frame:
Baseline, Week 116
Reported as:
Geometric mean · percent change in pTau-181
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Phosphorylated Tau (pTau-181)
percent change in pTau-181Placebo: DBTGantenerumab: DBT
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Phosphorylated Tau (pTau-181)0.1 (-6.50 to 7.16)-20.9 (-26.17 to -15.31)
Statistical analysis
  • Placebo: DBT vs Gantenerumab: DBT · ANCOVA · p = <0.001 · Percent difference in geometric mean: -21.0 · 95% CI -28.29 to -12.97
Other pre-specifiedPlasma Concentration of Gantenerumab
Time frame:
Pre-dose on Days 1, Weeks 24, 52 and 76; Post-dose on Day 4, Weeks 41, 103, and 115

No measurements were reported for this outcome.

Adverse events

Collected over DBT Period: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 128 weeks); OLE Period: From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 48 weeks) All cause mortality: DBT: Day 1 up to the end of study (up to approximately 164 weeks); OLE period: From OLE Day 1 up to the end of the study (up to approx. 86 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo: DBT5/477 (1%)63/474 (13.3%)296/474 (62.4%)
Gantenerumab: DBT7/498 (1.4%)61/501 (12.2%)358/501 (71.5%)
Placebo (DBT) to Gantenerumab: OLE0/13 (0%)1/13 (7.7%)8/13 (61.5%)
Gantenerumab (DBT) to Gantenerumab: OLE0/14 (0%)0/14 (0%)6/14 (42.9%)
Most frequent serious events
Showing 10 of 118
Most frequent serious events
EventPlacebo: DBTGantenerumab: DBTPlacebo (DBT) to Gantenerumab: OLEGantenerumab (DBT) to Gantenerumab: OLE
Femoral neck fractureInjury, poisoning and procedural complications0/4740/5011/130/14
FallInjury, poisoning and procedural complications5/4743/5010/130/14
PneumoniaInfections and infestations2/4744/5010/130/14
Urinary tract infectionInfections and infestations3/4744/5010/130/14
COVID-19Infections and infestations3/4743/5010/130/14
SyncopeNervous system disorders3/4741/5010/130/14
Acute coronary syndromeCardiac disorders2/4740/5010/130/14
COVID-19 pneumoniaInfections and infestations2/4741/5010/130/14
PyelonephritisInfections and infestations2/4741/5010/130/14
Humerus fractureInjury, poisoning and procedural complications2/4740/5010/130/14
Most frequent other events
Showing 10 of 44
Most frequent other events
EventPlacebo: DBTGantenerumab: DBTPlacebo (DBT) to Gantenerumab: OLEGantenerumab (DBT) to Gantenerumab: OLE
Amyloid related imaging abnormality-oedema/effusionNervous system disorders12/474114/5010/131/14
FallInjury, poisoning and procedural complications47/47447/5012/131/14
HypertensionVascular disorders35/47434/5012/130/14
Injection site reactionGeneral disorders31/47475/5010/131/14
HeadacheNervous system disorders50/47464/5010/130/14
NasopharyngitisInfections and infestations49/47445/5011/130/14
ArthralgiaMusculoskeletal and connective tissue disorders42/47439/5010/130/14
DiarrhoeaGastrointestinal disorders25/47439/5010/131/14
DizzinessNervous system disorders29/47439/5011/130/14
ArrhythmiaCardiac disorders1/4742/5011/130/14

Baseline characteristics

Intent-to-treat (ITT) analysis set included all participants randomized during the global phase, who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo: DBTGantenerumab: DBTTotal
Mean71.8 ± 7.471.6 ± 7.871.7 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)Placebo: DBTGantenerumab: DBTTotal
Female285288573
Male192210402
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo: DBTGantenerumab: DBTTotal
Hispanic or Latino119112231
Not Hispanic or Latino358386744
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo: DBTGantenerumab: DBTTotal
American Indian or Alaska Native131326
Asian7556131
Native Hawaiian or Other Pacific Islander000
Black or African American459
White385424809
More than one race000
Unknown or Not Reported000
Clinical Dementia Rating-Sum of Boxes (CDR-SB)
Clinical Dementia Rating-Sum of Boxes (CDR-SB)(score on a scale)Placebo: DBTGantenerumab: DBTTotal
Mean3.52 ± 1.543.67 ± 1.613.60 ± 1.58
08

Study locations

155 sites
  • Banner Alzheimer?s Institute
    Phoenix, Arizona 85006, United States
  • Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
  • Banner Sun Health Research Insitute
    Sun City, Arizona 85351, United States
  • Health Initiatives Research, PLLC
    Fayetteville, Arkansas 72703, United States
  • Fullerton Neurology and Headache Center
    Fullerton, California 92835, United States
  • Neurology Center of North Orange County
    Fullerton, California 92835, United States
  • Irvine Center for Clinical Research
    Irvine, California 92614, United States
  • Desert Valley Research
    Redlands, California 92374, United States
  • Southern California Research LLC
    Simi Valley, California 93065, United States
  • Yale University School Of Medicine
    New Haven, Connecticut 06519, United States
  • Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Accel Research Sites - CRU Tampa
    Bradenton, Florida 34201, United States
  • ClinCloud, LLC
    Maitland, Florida 32751, United States
  • Optimus U Corp
    Miami, Florida 33125, United States
  • Allied Biomedical Research Institute, Inc
    Miami, Florida 33155, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Intercoastal Medical Group
    Sarasota, Florida 34239, United States
  • Infinity Clinical Research, LLC
    Sunrise, Florida 33351, United States
  • Axiom Clinical Research of Florida
    Tampa, Florida 33609, United States
  • Emory University
    Atlanta, Georgia 30329, United States
  • Rush Alzheimer's Disease Cntr.
    Chicago, Illinois 60612, United States
  • American Health Network Institute, LLC
    Avon, Indiana 46123, United States
  • Brigham and Womens Hospital; Center for Alzheimer Research & Treatment
    Boston, Massachusetts 02115, United States
  • ActivMed Practices and Research
    Haverhill, Massachusetts 01830, United States
  • Boston Center for Memory
    Newton, Massachusetts 02459, United States
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
  • Missouri Memory Center
    Bolivar, Missouri 65613, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center; Dept of Neurological Sciences
    Omaha, Nebraska 68198-8440, United States
  • Cleveland Clinic Lou Ruvo; Center for Brain Research
    Las Vegas, Nevada 89106, United States
  • The Cognitive and Research Center of New Jersey
    Springfield, New Jersey 07081, United States
  • AD-CARE, University of Rochester Medical Center
    Rochester, New York 14620, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10314, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Behavioral Health Research
    Charlotte, North Carolina 28211, United States
  • Alzheimer's Memory Center
    Matthews, North Carolina 28105, United States
  • Raleigh Neurology Associates
    Raleigh, North Carolina 27607-6520, United States
  • Wake Forest University
    Winston-Salem, North Carolina 27157, United States
  • Neuro-Behavioral Clinical Research, Inc.
    Canton, Ohio 44718, United States
  • Cleveland Clinic; Cleveland Lou Ruvo Center for Brain Health ? Neurological Institute
    Cleveland, Ohio 44195, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Summit Research Network Inc.
    Portland, Oregon 97210, United States
  • Texas Neurology PA
    Dallas, Texas 75206, United States
  • Kerwin Medical Center
    Dallas, Texas 75231, United States
  • Alzheimers Disease & Memory Disorders Center; Department of Neurology Baylor College of Medicine
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77054, United States
  • Hospital Italiano
    Buenos Aires, C1181ACH, Argentina
  • Universidad Maimonides
    Caba, C1405BCK, Argentina
  • Instituto Geriatrico Nuestra Señora de las Nieves
    Capital Federal, C1427CCP, Argentina
  • CEN Centro Especializado en Neurociencias
    Cordoba, X5004FJF, Argentina
  • Instituto Kremer
    Córdoba, X5004AOA, Argentina
  • Instituto de Neurociencias San Agustín S.A.
    La Plata, B1902AVF, Argentina
  • Fundacion Scherbovsky
    Mendoza, M5500AYB, Argentina
  • AZ Sint Blasius (Dendermonde)
    Dendermonde, 9200, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • Jessa Zkh (Campus Virga Jesse)
    Hasselt, 3500, Belgium
  • Psicomed Estudios Médicos
    Antofagasta, 1270244, Chile
  • Biomedica Research Group
    Santiago, 7500710, Chile
  • Especialidades Medicas LYS
    Santiago, 7560356, Chile
  • Clinical Hospital Centre Zagreb;Clinic for Neurology
    Zagreb, 10000, Croatia
  • Aarhus Universitetshospital; Neurologisk Afd. F, Demensklinikken
    Aarhus N, 8200, Denmark
  • Rigshospitalet, Hukommelsesklinikken
    København Ø, 2100, Denmark
  • Svendborg Sygehus; Neurologisk afdeling N, Demensklinik Fyn
    Svendborg, 5700, Denmark
  • Terveystalo Ruoholahti
    Helsinki, 00180, Finland
  • University of Eastern Finland
    Kuopio, 70210, Finland
  • Yachiyo Hospital
    Aichi, 446-8510, Japan
  • Nagoya Ekisaikai Hospital
    Aichi, 454-8502, Japan
  • National Center for Geriatrics and Gerontology
    Aichi, 474-8511, Japan
  • Fukuoka University Hospital
    Fukuoka, 814-0180, Japan
  • National Hospital Organization Hiroshima-Nishi Medical Center
    Hiroshima, 739-0696, Japan
  • Hyogo Prefectural HarimaHimeji General Medical Center
    Hyogo, 670-8560, Japan
  • Tsukazaki Hospital
    Hyogo, 671-1227, Japan
  • Matsui Dietary and Dementia Clinic
    Hyogo, 673-0891, Japan
  • Kagawa Prefectural Central Hospital
    Kagawa, 760-8557, Japan
  • Rakuwakai Otowa Hospital
    Kyoto, 607-8062, Japan
  • Uji Takeda Hospital
    Kyoto, 611-0021, Japan
  • Rijikai Medical Corporation Katayama Medical Clinic
    Okayama, 710-0813, Japan
  • Kishiwada Tokushukai Hospital
    Osaka, 596-0042, Japan
  • National Hospital Organization Hizen Psychiatric Medical Center
    Saga, 842-0192, Japan
  • Medical corporation Ichiekai Itsuki Hospital
    Tokushima, 770-0852, Japan
  • Tokushima Hospital
    Tokushima, 776-8585, Japan
  • Dong-A University Hospital
    Busan, 49201, Korea, Republic of
  • Myongji Hospital
    Gyeonggi-do, 10475, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, 21565, Korea, Republic of
  • Inha University Hospital
    Incheon, 22332, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, 463-707, Korea, Republic of
  • Hanyang University Seoul Hospital
    Seoul, 04763, Korea, Republic of
  • Konkuk University Medical Center
    Seoul, 05030, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Seoul St Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • Ewha Womans University Hospital (Seoul)
    Seoul, 07804, Korea, Republic of
  • Ewha Womans University Mokdong Hospital
    Seoul, 07985, Korea, Republic of
  • Mexico Centre for Clinical Research
    Ciudad de México, Mexico CITY (federal District) 03100, Mexico
  • Hospital Universitario Dr Jose Eleuterio Gonzalez UANL; Depto.de NeurologíaPta.BajaConsulta
    Monterrey, Nuevo LEON 64460, Mexico
  • AVIX Investigación Clínica S.C
    Monterrey, Nuevo LEON 64710, Mexico
  • Hospital Angeles Culiacan; Neurociencias
    Culiacán Rosales, Sinaloa 80020, Mexico
  • Brain Research Center B.V
    Amsterdam, 1081 GN, Netherlands
  • O?rodek Badawczo-Naukowo-Dydaktyczny Chorób Ot?piennych w ?cinawie
    ?cinawa, 59-330, Poland

Showing the first 100 of 155 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Sep 2022, 49 months.

Results were first posted in Jan 2024, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2018
First posted
Feb 23, 2018
StartActual
Aug 22, 2018
Primary completionActual
Sep 23, 2022
CompletionActual
Nov 28, 2022
Results first posted
Jan 17, 2024
Last update
Jan 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03443973
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 23, 2018
Start date
Aug 22, 2018
Primary completion
Sep 23, 2022
Completion
Nov 28, 2022
Results posted
Jan 17, 2024
Last update
Jan 17, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gantenerumab

Start the discussion